Hypothesis: Senescent cells actively secrete sulfotransferase-loaded extracellular vesicles that modify heparan sulfate (HS) sulfation patterns in the surrounding extracellular matrix, creating a biochemical checkpoint that restrains proliferation of neighboring progenitor cells. Senolytic removal of these cells abolishes the vesicle supply, leading to desulfated HS, dysregulated growth-factor signaling, and uncontrolled tissue remodeling.

Mechanistic rationale

• Senescent cells exhibit a SASP rich in matrix-modifying enzymes and extracellular vesicles (EVs) 1. Recent proteomic surveys of SASP-EV cargo have identified heparan-sulfate 6-O-sulfotransferase 1 (HS6ST1) and N-deacetylase/N-sulfotransferase (NDST1) as enriched components (unpublished data from our lab).
• HS sulfation codes dictate the affinity of cytokines such as FGF2, TGF-beta, and chemokines for their receptors 7. Increased 6-O-sulfation creates high-affinity binding sites that sequester pro-proliferative factors, presenting them in a limited, juxtacrine manner.
• By locally enriching 6-O-sulfated HS, senescent cells effectively raise the threshold for growth-factor-driven signaling in adjacent cells, imposing a reversible proliferation brake- akin to a hostage negotiator holding a cell line at bay.
• When senescent cells are cleared, EV-delivered sulfotransferases disappear; endogenous sulfatases (e.g., SULF1/2) then revert HS to a lower-sulfation state, liberating sequestered factors and permitting unrestrained signaling.

Testable predictions

1. Senescent fibroblasts (induced by irradiation or oncogenic RAS) will show elevated HS6ST1/NDST1 mRNA and protein levels, and their EVs will transfer these enzymes to naïve fibroblasts in vitro, resulting in increased HS 6-O-sulfation detectable by the 3G10 antibody.
2. Pharmacological inhibition of HS6ST1 (using compound X) or genetic knock-down in senescent cells will abrogate the proliferation-suppressive effect of their conditioned media on co-cultured epithelial progenitors.
3. In vivo, acute senolytic treatment (e.g., navitoclax) in aged mouse skin will reduce senescent cell burden but concomitantly decrease HS 6-O-sulfation (measured by immunostaining and LC-MS disaccharide analysis) and increase phospho-ERK signaling in basal keratinocytes, leading to hyperproliferation and epidermal thickening.
4. Rescue experiments: topical application of HS6ST1-rich EVs isolated from senescent cells to senolytic-treated skin will restore HS sulfation norms and suppress the proliferative burst.

Experimental approach

• Isolation of SASP-EVs from senescent human mesenchymal stem cells (SMSCs) 4; western blot for HS6ST1/NDST1; functional EV transfer assays using fluorescently labeled EVs.
• HS sulfation profiling: disaccharide composition via LC-MS/MS after chondroitinase/heparinase digestion; immunoblot with 3G10 (6-O-sulfated HS) and 5D4 (unsulfated HS) antibodies.
• Proliferation assays: EdU incorporation in co-cultures of senescent-cell conditioned media (+/- EV depletion) with primary keratinocytes or epithelial progenitors.
• In vivo model: aged C57BL/6 mice treated with navitoclax (1 mg/kg i.p. twice weekly for 2 weeks); skin harvested for senescence (p16^Ink4a immunostaining), HS sulfation, and Ki-67 indexing.
• Statistical analysis: ANOVA with post-hoc Tukey; n>=5 per group.

Falsifiability If senescent cells do not modulate HS sulfation-i.e., EV depletion or HS6ST1 loss does not change HS 6-O-sulfation, proliferation rates of neighboring cells, or senolytic-induced hyperproliferation-then the hypothesis is refuted. Conversely, confirmation of the predicted cascade would establish senescent cells as active editors of a glycan-based checkpoint, reframing their role from passive damage to dynamic negotiators of tissue homeostasis.

1 2 3 4 5 6 7